KRAS and non-small cell lung carcinoma: Similarly, another pan-Raf inhibitor, lifirafenib (BGB-283), elicited an acceptable safety profile and clinical efficacy in patients with KRAS-mutated NSCLC and endometrial cancer (NCT02610361) [69].